跳至主要内容
临床试验/NCT02153281
NCT02153281已完成不适用

Neuroimaging MAO-B in Medication Free and Treatment Resistant Major Depressive Disorder Using Novel MAO-B Tracer

Centre for Addiction and Mental Health2 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2014年6月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
8
试验地点
2
主要终点
MAO-B VT levels measured with PET in MDE secondary to MDD

研究概览

简要总结

The purpose of this study is to determine if monoamine oxidase B (MAO-B) total distribution volume (VT), after phenelzine treatment and if so to what extent.

详细描述

Subjects will receive a PET and MRI scan before and after treatment with phenelzine.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 18-80 years of age
  • good physical health
  • Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) diagnosis of current major depressive episode (MDE)
  • DSM-IV diagnosis of major depressive disorder (MDD) verified by SCID for DSM-IV and a psychiatric consultation
  • greater than 17 on the 17 item HDRS (Hamilton Depression Rating Scale).
  • history of non-response to several different antidepressant classes

排除标准

  • herbal, drug or medication use (that affect CNS function)
  • suicide attempts
  • drug or medication use within eight weeks (+5 half lives of medication)
  • history of substance abuse or any neurotoxin use
  • history of psychotic symptoms
  • history of central nervous system (CNS) medical illness
  • current substance abuse
  • test positive on pregnancy test (for women)

研究组 & 干预措施

Phenelzine treatment

Experimental

Subjects will undergo a PET and MRI scan before and after the treatment.

干预措施: phenelzine treatment (Other)

结局指标

主要结局

MAO-B VT levels measured with PET in MDE secondary to MDD

时间窗: 8 weeks

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jeff Meyer

Head Neurochemical Imaging in Mood Disorders

Centre for Addiction and Mental Health

研究点 (2)

Loading locations...

相似试验